1. HBW Insight
  2. >>Leadership

US Wellness Market People News: Herbalife, Bobbie Baby, Optimum Nutrition, Nutrabolt, More

“Gronk” motivates for Optimum Health; Osaka promotes paid paternal leave with Bobbie Baby; MidOcean changes CEOs at QualiTech; Nutrabolt expands revenue chief’s oversight; Gratziani climbs higher on Herbalife ladder; and Enzymedica adds Natural Group COO.

• Source: Shutterstock

Stephan Gratziani moves up to president at Herbalife Nutrition Ltd. five months after he moved from operating a distributorship to be the health and wellness product direct seller’s chief strategy officer.

The Los Angeles-based firm on 2 January announced Gratziani’s promotion is part of its management succession planning process; he

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

US Consumer Health Executive News: CHPA Regulatory SVP, Kenvue CFO, PLT Sales Head

 
• By Malcolm Spicer

Former FDA OTC division director joins CHPA; PLT Health names global sales chief; and Kenvue loses CFO to Mattel, hires replacement from Kellanova.

People On The Move: Appointments At Haleon, Wellnex, Orkla

 
• By Tom Gallen

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.

Over The Counter: Everything You Wanted To Know About Real World Evidence, With IQVIA’s Volker Spitzer

 
• By David Ridley

HBW Insight finds out all about real world evidence and its potential for the OTC industry by chatting with IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer.

Makary’s Reorganization Decision A Turning Point For US FDA?

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.

More from HBW Insight

New Zealand Could Become First Country To Offer Gout Drug Allopurinol OTC

 
• By David Ridley

At the second attempt, New Zealand’s Medicines Classification Committee supported the Rx-to-OTC switch of allopurinol (100mg and 300mg) for people suffering from gout by specifically trained pharmacists.

Mitigating Tariff Impacts, Kenvue Adjusts Outlook

 
• By Malcolm Spicer

“The situation has evolved considerably” since Kenvue gave its initial full-year outlook in February, “and remains quite fluid,” says president and CEO Thibaut Mongon as firm reports Q1 net sales decreasing 3.9% to $3.7bn

Looming Tariffs Give Boost To Latest PCH Results While Cutting Costs In Response Takes Priority

 
• By Malcolm Spicer

Looming imposition of tariffs by Trump on imports from most every country had an influence on consumers during the January-March period, particularly on online shopping. Increasing product prices on the table, “but our efforts are going to start with cost savings,” says CFO Christine Sacco.